专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL237855D0 Modulation of androgen receptor expression 未知
公开(公告)号：IL237855D0
公开(公告)日：2015-05-31
申请号：IL23785515
申请日：2015-03-19
申请人： IONIS PHARMACEUTICALS INC , KIM YOUNGSOO , MACLEOD ROBERT A , ZHOU TIANYUAN , FREIER SUSAN M , SETH PUNIT P , SWAYZE ERIC , MONIA BRETT P
发明人： KIM YOUNGSOO , MACLEOD ROBERT A , ZHOU TIANYUAN , FREIER SUSAN M , SETH PUNIT P , SWAYZE ERIC , MONIA BRETT P
IPC分类号： C12N20060101
摘要： Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.

2. 发明专利

IL276007D0 Modulators of dnm2 expression 未知
公开(公告)号：IL276007D0
公开(公告)日：2020-08-31
申请号：IL27600720
申请日：2020-07-13
申请人： FREIER SUSAN M , MONIA BRETT P , IONIS PHARMACEUTICALS INC , GUO SHULING , MURRAY SUSAN F , BUI HUYNH HOA
发明人： FREIER SUSAN M , MONIA BRETT P , GUO SHULING , MURRAY SUSAN F , BUI HUYNH-HOA
IPC分类号： C12N15/113
摘要： The present embodiments provide methods, compounds, and compositions useful for inhibiting DNM2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DNM2.

3. 发明专利

IL262218A Modulation of androgen receptor expression 未知
公开(公告)号：IL262218A
公开(公告)日：2020-08-31
申请号：IL26221818
申请日：2018-10-08
申请人： IONIS PHARMACEUTICALS INC , KIM YOUNGSOO , MACLEOD ROBERT A , ZHOU TIANYUAN , FREIER SUSAN M , SETH PUNIT P , SWAYZE ERIC , MONIA BRETT P
发明人： KIM YOUNGSOO , MACLEOD ROBERT A , ZHOU TIANYUAN , FREIER SUSAN M , SETH PUNIT P , SWAYZE ERIC , MONIA BRETT P
IPC分类号： A61K31/7088 , A61K31/4166 , C12N15/113
摘要： Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.

4. 发明专利

IL262218D0 Modulation of androgen receptor expression 未知
公开(公告)号：IL262218D0
公开(公告)日：2018-11-29
申请号：IL26221818
申请日：2018-10-08
申请人： IONIS PHARMACEUTICALS INC , KIM YOUNGSOO , MACLEOD ROBERT A , ZHOU TIANYUAN , FREIER SUSAN M , SETH PUNIT P , SWAYZE ERIC , MONIA BRETT P
发明人： KIM YOUNGSOO , MACLEOD ROBERT A , ZHOU TIANYUAN , FREIER SUSAN M , SETH PUNIT P , SWAYZE ERIC , MONIA BRETT P
IPC分类号： C12N20060101
摘要： Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.

5. 发明专利

IL205536D0 MODULATION OF FACTOR 7 EXPRESSION 未知
公开(公告)号：IL205536D0
公开(公告)日：2010-12-30
申请号：IL20553610
申请日：2010-05-04
申请人： ISIS PHARMACEUTICALS INC , FREIER SUSAN M , MONIA BRETT P , ZHANG HONG , CROSBY JEFFREY R , ZHAO CHENGUANG
IPC分类号： C12N15/113

6. 发明申请

WO2012174154A1 MODULATION OF INFLAMMATORY RESPONSES BY FACTOR VII 审中-公开
标题翻译：由因子VII引起的炎症反应调节
公开(公告)号：WO2012174154A1
公开(公告)日：2012-12-20
申请号：PCT/US2012/042307
申请日：2012-06-13
申请人： ISIS PHARMACEUTICALS, INC. , CROSBY, Jeffrey, R. , REVENKO, Alexey , MONIA, Brett, P. , MACLEOD, Robert, A.
发明人： CROSBY, Jeffrey, R. , REVENKO, Alexey , MONIA, Brett, P. , MACLEOD, Robert, A.
IPC分类号： A61K31/7088
CPC分类号： A61K31/7088
摘要： Disclosed herein are antisense compounds and methods for modulating Factor VII and modulating an inflammatory disease, disorder or condition in an individual in need thereof. Inflammatory diseases in an individual such as arthritis and colitis can be treated, ameliorated or prevented with the administration of antisense compounds targeted to Factor VII. Provided herein are methods, compounds, and compositions for modulating levels of Factor VII mRNA and/or protein in an animal. Provided herein are methods, compounds, and compositions for modulating levels of Factor VII mRNA and/or protein in an animal in order to modulate an inflammatory response in the animal. Also provided herein are methods, compounds, and compositions for administering a therapeutically effective amount of a compound targeting Factor VII to an animal for ameliorating an inflammatory disease in an animal; treating an animal at risk for an inflammatory disease.
摘要翻译：本文公开了用于调节因子VII并调节有需要的个体的炎性疾病，病症或病症的反义化合物和方法。可以通过给予靶向因子VII的反义化合物来治疗，改善或预防个体中诸如关节炎和结肠炎的炎性疾病。本文提供了用于调节动物中因子VII mRNA和/或蛋白质水平的方法，化合物和组合物。本文提供了用于调节动物中因子VII mRNA和/或蛋白质水平的方法，化合物和组合物，以便调节动物中的炎症反应。本文还提供了用于向动物施用治疗有效量的靶向因子VII的化合物以改善动物的炎性疾病的方法，化合物和组合物; 治疗有风险的动物患有炎性疾病。

7. 发明申请

WO2010121074A8 MODULATION OF INFLAMMATORY RESPONSES BY FACTOR XI 审中-公开
公开(公告)号：WO2010121074A8
公开(公告)日：2010-10-21
申请号：PCT/US2010/031311
申请日：2010-04-15
申请人： ISIS PHARMACEUTICALS, INC. , MONIA, Brett, P. , CROSBY, Jeffrey, R. , MACLEOD, Robert, A. , FREIER, Susan, M.
发明人： MONIA, Brett, P. , CROSBY, Jeffrey, R. , MACLEOD, Robert, A. , FREIER, Susan, M.
IPC分类号： A61K48/00
摘要： Disclosed herein are antisense compounds and methods for modulating Factor XI and modulating an inflammatory disease, disorder or condition in an individual in need thereof. Inflammatory diseases in an individual such as arthritis and colitis can be ameliorated or prevented with the administration of antisense compounds targeted to Factor XI.

8. 发明申请

WO2006110775A3 ANTISENSE OLIGONUCLEOTIDES FOR MODIFYING EXPRESSION OF ACC1 AND ACC2 AND FOR CONTROLLING METABOLIC DISORDERS 审中-公开
标题翻译：用于修饰ACC1和ACC2表达的抗体寡核苷酸和用于控制代谢异常的反义寡核苷酸
公开(公告)号：WO2006110775A3
公开(公告)日：2010-07-01
申请号：PCT/US2006013536
申请日：2006-04-10
申请人： ISIS PHARMACEUTICALS INC , BHANOT SANJAY , MONIA BRETT P , GEISLER JOHN , MCKAY ROBERT , DOBIE KENNETH W
发明人： BHANOT SANJAY , MONIA BRETT P , GEISLER JOHN , MCKAY ROBERT , DOBIE KENNETH W
IPC分类号： C07H21/02 , A61K31/7088
CPC分类号： C12N15/1137 , A61K31/202 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12N2310/3521
摘要： Disclosed herein are compounds, compositions and methods for modulating the expression of ACCl or ACC2 or both in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
摘要翻译：本文公开了用于调节细胞，组织或动物中ACC1或ACC2或两者的表达的化合物，组合物和方法。还提供了所公开的化合物和组合物在制备用于治疗疾病和病症的药物中的用途。

9. 发明申请

WO2009143463A3 METHODS FOR MODULATING EXPRESSION OF CREB 审中-公开
标题翻译：调节CREB表达的方法
公开(公告)号：WO2009143463A3
公开(公告)日：2010-01-14
申请号：PCT/US2009045043
申请日：2009-05-22
申请人： ISIS PHARMACEUTICALS INC , UNIV YALE , SCHULMAN GERALD , BHANOT SANJAY , YU XING-XIAN , MONIA BRETT P
发明人： SCHULMAN GERALD , BHANOT SANJAY , YU XING-XIAN , MONIA BRETT P
IPC分类号： C12Q1/42 , A61K31/70
CPC分类号： C12N15/113 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12N2310/3525
摘要： Methods are provided for modulating CREB by administering a CREB-specific modulator. Also provided are methods for treating cardiovascular and metabolic disorders in a subject or delaying or preventing risk factors thereof through the modulation of CREB. The present invention is also directed to methods of decreasing lipid levels in a subject or for preventing or delaying the onset of a rise in lipid levels in a subject, comprising administering to said subject a CREB-specific inhibitor.
摘要翻译：提供了通过施用CREB特异性调节剂调节CREB的方法。还提供了通过调节CREB来治疗受试者的心血管和代谢紊乱或延缓或预防其危险因素的方法。本发明还涉及降低受试者中的脂质水平或用于预防或延迟受试者中脂质水平升高的发生的方法，包括向所述受试者施用CREB特异性抑制剂。

10. 发明申请

WO2007131238A8 COMPOUNDS AND METHODS FOR MODULATING EXPRESSION APOB 审中-公开
标题翻译：用于调制表达APOB的化合物和方法
公开(公告)号：WO2007131238A8
公开(公告)日：2009-12-17
申请号：PCT/US2007068403
申请日：2007-05-07
申请人： ISIS PHARMACEUTICALS INC , BHANOT SANJAY , GEARY RICHARD S , MCKAY ROBERT , MONIA BRETT P , SETH PUNIT P , SIWKOWSKI ANDREW M , SWAYZE ERIC E , WANCEWICZ EDWARD
发明人： BHANOT SANJAY , GEARY RICHARD S , MCKAY ROBERT , MONIA BRETT P , SETH PUNIT P , SIWKOWSKI ANDREW M , SWAYZE ERIC E , WANCEWICZ EDWARD
IPC分类号： A61K31/70 , C07H21/02 , C07H21/04 , C12N15/113 , C12Q1/68
CPC分类号： C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/341 , C12N2310/3515 , C12Y203/0102 , C12N2310/3521
摘要： The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
摘要翻译：本公开描述了短反义化合物，包括长度为化学修饰的高亲和力单体8-16单体的这类化合物。某些这样的短反义化合物可用于在增加的效力和改善的治疗指数的细胞，组织和动物中还原靶核酸和/或蛋白质。因此，本文提供了包含用于在体内降低靶RNA的高亲和力核苷酸修饰的短反义化合物。这样的短反义化合物在比以前描述的反义化合物低的剂量下是有效的，允许降低毒性和治疗成本。此外，所述短反义化合物具有更大的口服给药潜力。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式